PFIZER INC (PFE)
2025-06-29 | 2025-03-30 | 2024-09-29 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenues | 14,653 | 13,715 | 17,702 | 13,283 |
| Research and development expenses | 2,482 | 2,203 | 2,598 | 2,696 |
| Acquired in-process research and development expenses | 2 | 9 | 13 | 6 |
| Other (income)/deductionsnet | -739 | -953 | -243 | -1,107 |
| Cost of sales | 3,778 | 2,845 | 5,263 | 3,300 |
| Restructuring charges and certain acquisition-related costs | -18 | 678 | 313 | 1,254 |
| Amortization of intangible assets | 1,211 | 1,211 | 1,312 | 1,307 |
| Selling, informational and administrative expenses | 3,415 | 3,031 | 3,244 | 3,717 |
| Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss) | 3,044 | 2,785 | 4,715 | -103 |
| Provision/(benefit) for taxes on income/(loss) | 141 | -189 | 234 | -134 |
| Income from continuing operations | 2,903 | 2,973 | 4,481 | 31 |
| Discontinued operationsnet of tax | 25 | - | -8 | 17 |
| Net income before allocation to noncontrolling interests | 2,928 | 2,973 | 4,473 | 48 |
| Less net income attributable to noncontrolling interests | 18 | 6 | 8 | 7 |
| Net income attributable to pfizer inc. common shareholders | 2,910 | 2,967 | 4,465 | 41 |
| Net income attributable to pfizer inc. common shareholders (in dollars per share) | 0.51 | 0.52 | 0.79 | 0.01 |
| Net income attributable to pfizer inc. common shareholders (in dollars per share) | 0.51 | 0.52 | 0.78 | 0.01 |
| Weighted-average shares--basic (in shares) | 5,685,000,000 | 5,675,000,000 | 5,667,000,000 | 5,666,000,000 |
| Weighted-average shares--diluted (in shares) | 5,706,000,000 | 5,710,000,000 | 5,705,000,000 | 5,696,000,000 |